Semil Mehta, MD
Critical Care Medicine · Bannockburn, ILNPI 1972596021
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,225 of the $8,873 with a category attached, or 70.2%. Boehringer Ingelheim accounts for 83.1% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $7,908, more than ten times the $49 reported in 2019. Among critical care medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $197.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- AstraZeneca$613
- United Therapeutics Corporation$431
- Verona Pharma, Inc.$122
- Johnson & Johnson$57
- Harmony Biosciences LLC$53
- plus $221 from 8 others
What the payments were for
- Consulting fees$6,22570%
- Travel & lodging$8049%
- Food & beverage$1,79520%
- Education$491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $7,377 |
| AstraZeneca | 13 | $613 |
| United Therapeutics Corporation | 4 | $431 |
| Verona Pharma, Inc. | 1 | $122 |
| Johnson & Johnson | 1 | $57 |
| Harmony Biosciences LLC | 4 | $53 |
| 3b Medical, Inc. | 1 | $39 |
| Genentech USA, Inc. | 1 | $38 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Insmed, Inc. | 2 | $31 |
| Covis Pharma GmbH | 1 | $26 |
| Shionogi Inc | 1 | $22 |
| Electromed, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,873 in reported general payments places this provider in the 90th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $118,380 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 81 | $47,101 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $32,343 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $28,639 |
| Arnuity ElliptaFluticasone Furoate | 39 | $19,457 |
| NeuproRotigotine | 14 | $13,110 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $10,900 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,419 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $8,569 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $8,304 |
| DuleraMometasone/Formoterol | 17 | $7,176 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 142 | $4,538 |
| Fluticasone Propionate HfaFluticasone Propionate | 15 | $4,484 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $4,129 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $7,377 | $10,41912 claims |
| AstraZenecaSymbicort | $613 | $8,30414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in Bannockburn
- Brian ReichardtO Fallon$892K
- Michael CutticaChicago$402K
- Daniel DillingMaywood$208K
- Israel RubinsteinChicago$107K
- John RickelmanQuincy$90K
- Abbas Al-QamariChicago$40K
- Husam NayefPalos Park$24K
- Nureain MirzaOak Lawn$22K
- Edward GarrityBurr Ridge$20K
- Fadi AldaasChicago Ridge$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.